Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06631040
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-06
Brief Title:
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-Acute Lymphocytic Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Immunotherapy has shown promise in treating hematological malignancies including resistant B-ALL One approach is CAR-NK cell therapy which involves genetically modifying natural killer NK cells to target specific cancer antigens While CAR-NK therapy offers advantages over CAR-T therapy such as reduced immune system reactions and lower production time and cost challenges remain regarding antitumor efficacy and the tumor microenvironment Preclinical and early clinical studies have targeted various antigens including CD19 with CAR-NK cells in resistant B-ALL To further investigate the potential of anti-CD19 CAR-NK cell therapy this study aims to evaluate its safety and determine the maximum tolerated dose MTD in patients who have not responded to standard treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None